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ABSTRACT:
The organocatalytic asymmetric transfer hydrogenation of N-alkyl arylimino esters for the direct synthesis of N-alkylated arylglycinate esters is reported. High yields and enantiomeric ratios were obtained, and the tolerance to a diverse set of functional groups facilitated the preparation of more complex molecules as well as intermediates for active pharmaceuticals. A simple recycling protocol was developed for the Brønsted acid catalyst which could be reused through five cycles with no loss of activity or selectivity.
Despite considerable recent interest in peptides as candidate drugs thanks to their potential for tackling complex targets (e.g. protein-protein interaction modulation) and improved selectivity and toxicity profiles, their use is strongly hampered by their poor pharmacokinetic profile, including short circulating plasma half-life and poor potential for oral absorption. Thus, the development of novel chemical strategies to stabilize peptides and improve their pharmacokinetic properties has gained in profile. 1 Among the strategies developed to circumvent these limitations, 1,2 the incorporation of N-alkylated amino acids is considered an effective way to enhance metabolic stability, lipophilicity and membrane-permeability.
2 For example, the clinically-used immunosuppressive natural product cyclosporine A features seven N-methylated residues and, although violating the Lipinski rules for oral bioavailability, has an excellent pharmacokinetic profile.
3 N-Alkylation modifies the steric constraints of the peptide chain and the hydrogen bond patterns, offering opportunities for broader conformational design. 2, 4 Moreover, N-allylated amino acids have been used in approaches to stabilize secondary structures such as Arora's hydrogen bond surrogate strategy, 5 and in the preparation of stapled peptides. 6 In view of these developments, there is significant interest in the development of new methods to provide optically pure N-alkyl amino acids. Arylglycines belong to a family of non-proteinogenic amino acids 7 which are present in a wide range of natural products of pharmaceutical relevance (such as the pristinamycines 8 and ramoplanines 9 Figure 1 ) as well as semi-synthetic drugs (such as penicillins and cephalosporins, Figure 1) . 10 Classical methodologies for the preparation of N-alkylated arylglycines can be grouped into three processes: reductive amination, reductive ring opening of 5-oxazolidinones and N-alkylation. 2a However, many of these methods are either lengthy and/or involve protection/deprotection sequences often associated with racemization of the sensitive stereocentre. 7 To our knowledge, only two asymmetric catalytic methodologies have been reported towards the direct synthesis of N-alkyl arylglycines. 11 Organocatalytic hydrosilylation of N-benzyl iminoesters was reported with moderate enantioselectivity (up to 71% ee, Scheme 1), 11a while an asymmetric Rh-catalyzed hydrogenation of aldimines proceeding via dynamic kinetic resolution gave moderate-tolow enantiomeric ratios. 11b In this context, the development of a modular asymmetric catalytic methodology for the preparation of a wide range of arylglycines bearing different N-alkyl chains is still needed. BINOL-derived chiral Brønsted acids have proved to be efficient catalysts for asymmetric imine transfer hydrogenation and reductive aminations of carbonyl compounds. 12 The groups of You 13b and Antilla 13c reported the organocatalytic transfer hydrogenation of protected -iminoesters, obtaining -amino esters with high yields and enantioselectivities (Scheme 1), but the substrate scope was limited to N-aryl imines. Inspired by the work of List using BINOL-derived disulfonimides 3 to promote the asymmetric transfer hydrogenation of N-alkyl ketimines, 1. We report herein the successful direct synthesis of enantioenriched arylglycines 2 bearing diverse functionalized N-alkyl substituents (Scheme 1). Scheme 1. Asymmetric catalytic synthesis of arylglycines. Gratifyingly, we found that reduction of arylimino ester 1aa using 3a as the catalyst, Hantzsch ester 6 as hydrogen donor and Boc2O in toluene in the presence of 5Å molecular sieves furnished the desired Boc-protected N-methyl amino ester in a 95% NMR yield with a high enantiomeric ratio (e.r. = 81:19, Table 1 , Entry 1). It was observed that apolar solvents are needed to obtain both high yields and enantiomeric ratios, but the best result was obtained in toluene (Table 1 , entries 1-6).
Different hydrogen donors were also tested and the best results were obtained using Hantzsch ester 6 (see Supporting Information). As reported by List, the presence of Boc2O as an trapping agent is needed to achieve high yields. 14 Other trapping groups could be used maintaining comparable levels of selectivity (see Supporting Information). BINOL-derived phosphoric acid 4a and triflyl phosphoramide 5a gave only moderate yields and low selectivities (entries [7] [8] . The effect of the substituent in the 3/3'-position of the binaphthyl moiety of the catalyst was investigated. Aryl substituents with electron-withdrawing groups in the para position gave the highest levels of enantioselectivity (entries 1, 9-14), with the best result obtained with para-nitrophenyl substituted disulfonimide 3h, affording the Boc-protected amino ester in a 95% NMR yield and 90:10 enantiomeric ratio; deprotection gave a 90% isolated yield of N-methyl amino ester 2aa. 15 The e.r. could be further increased by decreasing the reaction temperature to 0°C (entry 15). With the optimal reaction conditions in hand, we next examined the generality of this transformation, commencing with reduction of various N-methyl iminoesters. Different ester groups were well tolerated, with ethyl esters affording the best results (Figure 2 ). The replacement of the ester functionality by a tertiary amide gave the corresponding amide but with low yield and enantioselectivity. Variation in the aryl substituent was probed. Both para and meta substituents on the aryl ring were well tolerated but the introduction of ortho substituents led to a decrease in both activity and enantioselectivity (Figure 2 ). Iminoester 1ea with a tert-butyl substituent in the para position performed particularly well and the N-methyl arylglycine 2ea could be prepared on gram-scale maintaining the excellent yield and enantioselectivities (Supporting Information). Electron-donating groups on the aryl ring led to an increase in the enantiomeric ratio while electron-withdrawing substituents decreased both activity and selectivity (Figure 2) . Finally, the organocatalytic transfer hydrogenation was compatible with the introduction of heteroaromatic rings into the imino ester; however, only moderate enantioselectivities were obtained (Figure 2) . The effect of various N-alkyl groups was then investigated (Figure 3) . Pleasingly a range of substituents with different chain lengths and bearing a variety of functional groups (allyl, homopropargyl, azide, bromo, silyl ether) were very well tolerated, maintaining excellent enantioselectivities albeit that longer reaction times were needed. Notably, the ready access to N-allyl, homopropargyl and azidoalkyl amino acids will facilitate the preparation of stapled peptides. Together, these results represent the first asymmetric transfer hydrogenation of N-alkylated arylimino esters, delivering varied N-alkyl arylglycine esters directly with good to excellent selectivities. Furthermore, the functional groups present on the N-alkyl substituents could be used for further transformations to construct more complex chiral compounds. For example, ester reduction afforded amino alcohol 7 in good yield, while the Fmoc-protected aminoacid 8, which could potentially be directly used in the construction of synthetic peptides, was easily prepared from amino ester 1ea (Figure 4 ). 16 We were also able to perform a Cu-catalyzed click reaction of azide containing amino ester 1sa to afford the biotinylated compound 9 in high yield, offering the potential for incorporation in bioactive peptides and use as a tool in chemical biology (Figure 4) . 17 N-Heterocycles could also be elaborated from N-alkyl amino esters. Azetidine containing amino ester 10 was generated by internal nucleophilic substitution of an alkyl bromide, while piperazone 11 was obtained by reductive cyclization of azido ester 2sa. In all cases the products were obtained maintaining the excellent enantioselectivities ( Figure 4 ). Finally, we demonstrated the applicability of our method to the direct synthesis of a marketed drug, by completing the synthesis of morpholinone 12c which is an intermediate for the preparation of the antiemetic drug Aprepitant ( Figure 5) . 18, 19 This is the first catalytic asymmetric method developed to date for the preparation of compound 12c. In our effort to increase the applicability and sustainability of the process, we developed a protocol for the recovery and reuse of the chiral Brønsted acid catalyst (Table 2) . Simply by transferring the crude reaction mixture to a commercially available anion exchange resin column followed by solvent elution allowed us to recover the Boc-protected amino ester. A final acid wash of the column eluted the Brønsted acid catalyst, which could be recovered nearly quantitatively. In this way, the catalyst was reused up to five times while maintaining excellent yields and selectivities. This represents the first successful protocol for the recovery and reuse of a chiral Brønsted acid catalyst, and should find wider applicability. In summary, we have developed an organocatalytic transfer hydrogenation of N-alkylated arylimino esters which gives direct access to N-alkyl arylglycines. Excellent yields and enantiomeric ratios were achieved for a wide range of substrates with a range of (hetero)aryl substituents as well as diverse functionalised N-alkyl chains. The broad synthetic applicability of these products, combined with the opportunity for catalyst recycling offers great potential utility.
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